Author: Customer Service

SOUTHLAKE, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) — Renewal Fuels, Inc. (OTC: RNWF) (“RNWF” “American Fusion” or the “Company”), announced today the appointment of Dr. John E. Brandenburg, Ph.D., as Chief Technology Officer of Kepler Fusion Technologies, effective immediately. Dr. Brandenburg is a senior plasma physicist with more than four decades of experience in fusion energy, advanced propulsion, and applied plasma physics. He brings deep technical expertise to the Company’s mission of commercializing the Texatron™ aneutronic fusion platform. Dr. Brandenburg’s career includes senior scientific roles at Lawrence Livermore National Laboratory, Sandia National Laboratories, The Aerospace Corporation, the Florida Space Institute at Kennedy Space Center, and Orbital Technologies Corporation (ORBITEC). He has held U.S. government...

COMPLETION OF SOCIETE GENERALE’S EUR 1 BILLION SHARE BUY-BACK PROGRAMME FOR CANCELLATION PURPOSE Regulated Information Paris, 6 February 2026 Societe Generale announces the completion of its share buy-back programme for cancellation purpose* which began on 19 November 2025. Societe Generale has repurchased 15,170,791 shares which will later be cancelled. The purchases performed from 2 to 6 February 2026 are described below. Press contacts:Jean-Baptiste Froville_+33 1 58 98 68 00_ jean-baptiste.froville@socgen.com Fanny Rouby_+33 1 57 29 11 12_ fanny.rouby@socgen.com * Societe Generale published on 21 November 2025 morning the new description of the share buy-back programme relating to the 19th resolution of the Combined general meeting of shareholders of 20 May 2025. Purchases performed by Societe Generale during the period Issuer name:...

Paris, February 6th, 2026 INFORMATION ON THE FINANCIAL TERMS OF THE DEPARTURE OF PAULO CASTELLARI, CHIEF EXECUTIVE OFFICER (According to the recommendations of the Afep-Medef corporate governance code) During its meeting held on 1 February 2026, the Board of Directors decided the departure of Mr. Paulo Castellari from his duties as Chief Executive Officer, with effect as of the same date, and, upon the recommendation of its Compensation and Governance Committee, set the financial terms of his departure in accordance with the compensation policy approved by the General Shareholders’ Meeting of 26 May 2025. Those terms are detailed below. Fixed remuneration paid in respect of fiscal year 2026 The fixed remuneration to be paid to Mr. Paulo Castellari for fiscal year 2026 will amount to 66,666.6 euros, corresponding to the prorated portion...

EVANSVILLE, Ind., Feb. 06, 2026 (GLOBE NEWSWIRE) — Old National Bancorp (“Old National”) has appointed Joe Chasteen to the role of Chief Revenue Enablement Officer, a newly-created strategic leadership position focused on organic growth and revenue generation. Chasteen brings more than 27 years of business banking and enterprise leadership experience to Old National, previously holding senior roles at several large financial institutions across the country. Across those organizations Joe has led large teams spanning multiple regions, building sales strategies, guiding integrations, and supporting the growth of business clients of all sizes. A core focus of the Chief Revenue Enablement Officer role will be establishing and reinforcing Old National’s enterprise-wide disciplined sales processes, including further advancing the use...

SOUTH JORDAN, Utah, Feb. 06, 2026 (GLOBE NEWSWIRE) — Cricut®, Inc. (NASDAQ: CRCT) has introduced the next evolution of its heat press line, the Cricut EasyPress® SE, announced on Feb. 6, 2026. Designed to remove common pain points from the heat transfer process, Cricut EasyPress SE delivers a simplified, friction-free pressing experience while maintaining the quality and reliability that makers have come to expect from the Cricut brand. Trusted Performance and VersatilityEngineered for consistent, long-lasting results, Cricut EasyPress SE provides professional-quality heat transfers without the complexity or size of an industrial press. It supports a wide range of materials, including iron-on (HTV), Infusible Ink™, sublimation, and DTF (direct-to-film), helping users achieve durable personalization that holds up over time. Consistent...

INVITATION TO THE MEDIA & ANALYST CONFERENCE February 27, 2026, 11:00 am Results 2025 and outlook Steinhausen, February 6, 2026 – We cordially invite you to the media, analyst and investor conference of Schweiter Technologies. In addition to information on the 2025 results, we are pleased to give you an outlook for 2026. The media conference will take place on February 27, 2026 at 11:00 a.m. CET at the Hotel Marriott, Neumühlequai 42, in Zurich and will simultaneously be transmitted in a webcast: https://www.webcast-eqs.com/schweiter-2025-results. Roman Sonderegger (CEO) and Urs Scheidegger (CFO) look forward to your participation. Please confirm your physical participation at the Marriott Hotel no later than February 19, 2026 by email to info@schweiter.com. Please find the Media release in the PDF attached:  Media release (PDF)

Rexel: Statement relating to the total number of shares and voting rights pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Rules of the French Autorité des marchés financiersDate Number of shares Number of voting rights2026-01-31 296,096,004 Theoretical number of voting rights(1): 296,096,004Exercisable number of voting rights(2): 293,291,344  (1)         Number of voting rights including treasury shares deprived from voting rights.(2)         Number of voting rights excluding treasury shares deprived from voting rights.AttachmentStatement relating to the total number of shares and voting rights as of January 31, 2026

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel, Switzerland Approximately 466,000-square-foot site with AI-enabled discovery capabilities, expected to house about 1,000 employees Part of a USD 23 billion US investment to expand R&D and advanced manufacturing to reach more patientsEast Hanover, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical Research center in San Diego, California, designed to provide world-class scientific infrastructure and drug-discovery capabilities to advance the company’s pipeline for patients.   Once operational in 2029, the approximately 466,000-square-foot facility is expected to house about 1,000 Novartis employees and integrate...

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel, Switzerland Approximately 466,000-square-foot site with AI-enabled discovery capabilities, expected to house about 1,000 employees Part of a USD 23 billion US investment to expand R&D and advanced manufacturing to reach more patientsBasel, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical Research center in San Diego, California, designed to provide world-class scientific infrastructure and drug-discovery capabilities to advance the company’s pipeline for patients. Once operational in 2029, the approximately 466,000-square-foot facility is expected to house about 1,000 Novartis employees and integrate seamlessly...

BEVERLY HILLS, California, Feb. 06, 2026 (GLOBE NEWSWIRE) — Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, is pleased to provide a corporate update, highlighting an overview of developments in its subsidiaries, Oricidin, Bio-Convert and NoviThera, and a status of the Company’s Nasdaq uplisting application. Orocidin The first pilot efficacy study in patients is anticipated to start in Q3 2026 at the University of Copenhagen in Denmark. In order to start the efficacy study, it will begin upon completion of the GMP (Good Manufacturing Practice) for the clinical use of the product. Additionally, a pivotal 8-week toxicology study is about to be initiated and is expected...